INHIBRX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.11 USD | +0.09% |
|
-0.70% | -10.24% |
| May. 31 | Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Biotechnology Select Industry Index | CI |
| May. 31 | Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Global BMI Index | CI |
ETFs positioned on Inhibrx, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.20% | 12 M€ | -.--% | - | |
| 0.09% | 2 M€ | -.--% | ||
| 0.07% | 0 M€ | 0.00% | - | |
| 0.05% | 0 M€ | 0.00% | - | |
| 0.04% | 7 M€ | -.--% | - | |
| 0.01% | 746 M€ | -.--% | - | |
| 0.00% | 9 M€ | -.--% | - | |
| 0.00% | 9 M€ | +9.86% | - | |
| 0.00% | 17 M€ | +4.00% | - | |
| 0.00% | 34 M€ | +3.86% | - |
Inhibrx, Inc. is a clinical-stage biopharmaceutical company. The Company is a wholly owned subsidiary of Sanofi S.A.
Calendar
2024-08-04
- Q2 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
34.11
USD
Average target price
35.5
USD
Spread / Average Target
+4.08%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.24% | 1.79B | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- INBX Stock
- Funds and ETFs Inhibrx, Inc.
